Oncothyreon Raises $14.9M
Oncothyreon (NASDAQ: ONTY), the Seattle-based developer of cancer drugs, said today it has raised $14.9 million through a private placement transaction. The company sold 4.24 million securities units (a combination of common stock and warrants) at $3.50 apiece. That represents a 7.2 percent discount to the 30-day trailing average stock price, Oncothyreon said. JMP Securities led the deal, and Roth Capital Partners served as the co-agent.